Aim Immunotech Inc 's Cash & cash equivalent grew by 92.94 % in the Q1 2026 sequentially, while Current Liabilities decreased, this led to improvement in Aim Immunotech Inc 's Quick Ratio to 1, Quick Ratio remained below Aim Immunotech Inc average.

Within Biotechnology & Pharmaceuticals industry 106 other companies have achieved higher Quick Ratio than Aim Immunotech Inc in first quarter 2026. While Quick Ratio total ranking has improved so far during the Q1 2026 to 1599, from total ranking in the fourth quarter 2025 at 2326.

Explain Quick Ratio?
How much Cash & cash equivalents AIM�s has?
What are AIM�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AIM/financial-strength

https://api.csimarket.com/api/v1/companies/AIM/fundamentals

https://api.csimarket.com/api/v1/companies/AIM/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

AIM Quick Ratio	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1
Y / Y Current Liabilities Change	-38.21 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	161.64 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	1	Subscribe	Subscribe	Subscribe	Subscribe
AIM's Total Ranking	# 1599	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-1.41 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	92.94 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 107
Healthcare Sector	# 584
Overall Market	# 1599

Quick Ratio Statistics
High	Average	Low
51.09	13.88	0.02
(Sep 30 2021)		(Jan 31 2012)

Financial Statements
Aim Immunotech Inc 's Current Liabilities	$ 6 Millions	Visit AIM's Balance sheet
Aim Immunotech Inc 's Cash & cash equivalent	$ 6 Millions	Visit AIM's Balance sheet
Source of AIM's Sales		Visit AIM's Sales by Geography

Cumulative Aim Immunotech Inc 's Quick Ratio

AIM's Quick Ratio for the trailling 12 Months

AIM Quick Ratio	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-30.75 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-48.18 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.47	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 2142	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-12.36 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	42.54 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to AIM Financial Strength Comparisons >> Go to Compare AIM Quick Ratio to its Competitors

On the trailing twelve months basis AIM Cash & cash equivalent more than doubled by 161.64 % in Q1 2026 year on year, while Current Liabilities decreased to $6 millions, this led to increase in in Aim Immunotech Inc 's Quick Ratio to 0.47, Quick Ratio remained below AIM average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Aim Immunotech Inc . While Quick Ratio overall ranking has improved so far to 2986, from total ranking during the twelve months ending fourth quarter 2025 at 3000.

Explain Quick Ratio?
How much Cash & cash equivalents AIM�s has?
What are AIM�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 143
Healthcare Sector	# 904
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
45.29	7.93	0.1
(Mar 31 2022)		(Jun 30 2025)

Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Mar 31 2026 MRQ Cash & cash equivalent	Mar 31 2026 MRQ Current Liabilities
Adaptive Biotechnologies Corporation	2.51	$ 218.334 Millions	$ 87.011 Millions
Iovance Biotherapeutics inc	2.48	$ 313.443 Millions	$ 126.521 Millions
Novavax inc	2.31	$ 790.332 Millions	$ 342.461 Millions
C4 Therapeutics Inc	2.25	$ 61.274 Millions	$ 27.249 Millions
Moderna Inc	2.17	$ 5,205.000 Millions	$ 2,395.000 Millions
Regenxbio Inc	2.12	$ 150.491 Millions	$ 71.110 Millions
Exelixis Inc	2.10	$ 777.207 Millions	$ 370.975 Millions
Quince Therapeutics Inc	2.07	$ 18.163 Millions	$ 8.768 Millions
Autolus Therapeutics Plc	2.06	$ 130.951 Millions	$ 63.599 Millions
Mink Therapeutics Inc	2.02	$ 9.526 Millions	$ 4.718 Millions
Tarsus Pharmaceuticals Inc	2.00	$ 286.540 Millions	$ 143.508 Millions
Adma Biologics Inc	1.91	$ 138.153 Millions	$ 72.365 Millions
Vivosim Labs Inc	1.80	$ 5.024 Millions	$ 2.785 Millions
Dyadic International Inc	1.76	$ 5.608 Millions	$ 3.184 Millions
Calidi Biotherapeutics Inc	1.73	$ 6.631 Millions	$ 3.836 Millions
Passage Bio Inc	1.66	$ 33.336 Millions	$ 20.104 Millions
Neurocrine Biosciences Inc	1.58	$ 1,316.200 Millions	$ 831.700 Millions
Jasper Therapeutics Inc	1.57	$ 14.144 Millions	$ 8.996 Millions
Elutia Inc	1.56	$ 28.488 Millions	$ 18.225 Millions
Ocugen Inc	1.54	$ 31.855 Millions	$ 20.708 Millions
Protalix Biotherapeutics inc	1.52	$ 41.712 Millions	$ 27.388 Millions
Eloxx Pharmaceuticals Inc	1.49	$ 6.363 Millions	$ 4.264 Millions
Atara Biotherapeutics Inc	1.48	$ 8.360 Millions	$ 5.645 Millions
Twist Bioscience Corporation	1.43	$ 171.671 Millions	$ 119.976 Millions
Bio techne Corp	1.37	$ 209.819 Millions	$ 153.278 Millions
Pelthos Therapeutics Inc	1.28	$ 31.976 Millions	$ 25.003 Millions
Coherus Oncology inc	1.26	$ 167.048 Millions	$ 132.332 Millions
Biocryst Pharmaceuticals Inc	1.22	$ 239.254 Millions	$ 195.391 Millions
Sana Biotechnology Inc	1.17	$ 101.136 Millions	$ 86.265 Millions
Curis Inc	1.09	$ 15.001 Millions	$ 13.745 Millions

Date modified: 2026-10-05T11:03:40+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.